Abstract:Cancer therapy targets specific metabolic pathways or a single gene. This may result in low therapeutic effects due to drug selectivity and drug resistance. Recent studies revealed that the mitochondrial membrane potential and transmembrane permeability of cancerous mitochondria are differed from normal mitochondria. Thus, chemotherapy targeting cancerous mitochondria could be an innovative and competent strategy for cancer therapy. Previously, our work with a novel group of mitochondria targeting small molecules presented promising inhibitory capability toward various cancer cell lines and suppressed adenosine triphosphate (ATP) generation. Therefore, it is critical to understand the anticancer effect and targeting mechanism of these small molecules. This study investigated the inhibitory activity of mitochondria targeting small molecules with human cervical cancer cells - HeLa to further explore their therapeutic potential. HeLa cells were exposed to 10 mu M of syn-thesized compounds and presented elevation in intracellular reactive oxygen species (ROS) level, impaired mitochondrial membrane potential and upregulation of apoptosis as well as necrosis. In vivo, HeLa cell tumor-bearing BALB/c nude mice were treated with mitochondria targeting small molecules for 12 days consecu-tively. Throughout this chemotherapy study, no deleterious side effects nor the appearance of toxicity was observed. Furthermore, mitochondria targeting small molecules treated groups exhibited significant down-regulation with both tumor volume and tumor weight compared to the Doxorubicin (DOX) treated group. Thus, inhibition of mitochondrial ATP synthesis, activation of intracellular ROS production, down-regulation of mitochondrial membrane potential and upregulation of apoptosis and necrosis rates are the indications of cancer therapy. In this work, we examined the anticancer capability of four mitochondria targeting small molecules in vitro and in vivo, and demonstrated a novel therapeutic approach in cancer therapy with tremendous potential.

Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds.

Mitocans Revisited: Mitochondrial Targeting as Efficient Anti-Cancer Therapy

Natural compounds modulating mitophagy: Implications for cancer therapy

Targeting Cancer Cell Mitochondria As a Therapeutic Approach.

Small Mitochondria-Targeting Molecules As Anti-Cancer Agents

Mitochondria-Shaping Proteins and Chemotherapy

Mitochondria as a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents

TPP-based mitocans: a potent strategy for anticancer drug design

Mitochondria Targeting as an Effective Strategy for Cancer Therapy

Targeting the Mitochondria with Pseudo- Stealthy Nanotaxanes to Impair Mitochondrial Biogenesis for Effective Cancer Treatment

Progress in the Study of Anti-Tumor Drugs Targeting Mitochondria

Investigating Therapies Targeting Druggable Targets of Mitochondria: Exploring the Efficacy for the Treatment of Cancer

Targeting Cancer Cell Mitochondria As a Therapeutic Approach: Recent Updates

Targeting Mitochondrial Dysfunctions in Pancreatic Cancer Evokes New Therapeutic Opportunities

Therapeutic Potential of Terpenoids in Cancer Treatment: Targeting Mitochondrial Pathways

Recent Progress in Mitochondria-Targeted Drug and Drug-Free Agents for Cancer Therapy

Mitochondrial dysfunction-targeted nanosystems for precise tumor therapeutics

Biological Evaluation of Mitochondria Targeting Small Molecules As Potent Anticancer Drugs.

Mitochondria-targeted drug delivery system for cancer treatment.

Natural products and mitochondrial allies in colorectal cancer therapy

Targeting Mitochondrial Metabolic Reprogramming As a Potential Approach for Cancer Therapy